In this SOHO Insider interview from the 2026 European Hematology Association Congress, Irina Murakhovskaya, MD, an assistant professor at Albert Einstein College of Medicine, discusses the phase 2/3 ENERGY trial, which evaluated the efficacy and safety of intravenous nipocalimab in patients with warm autoimmune hemolytic anemia.
Warm autoimmune hemolytic anemia is a rare disease with no current approved therapy. In the trial, the investigators reported that nipocalimab had durable responses with a favorable safety profile.
Leave feedback about this